Answers are grounded in this paper and cite their sources.
Longitudinal analysis reveals disparities in GLP-1RA and SGLT2i prescriptions among racial groups in type 2 diabetes, indicating urgent need for equity interventions.
Introduction and Objective: GLP-1RA and SGLT2i classes reduce glycemia, improve cardiometabolic risk factors, and cardiovascular and renal disease risk for adults with type 2 diabetes. However, Hispanic, Black, and Asian populations are less likely to initiate the drugs than non-Hispanic White patients. Our objective was to assess longitudinal trends in prescription of GLP-1RA and SGLT2i medications by race and ethnicity from 2016-2023. Methods: We analyzed EHR data from adults with type 2 diabetes with at least one indication for GLP-1RA or SGLT2i - 1) CVD or DKD, 2) obesity, or 3) high HbA1c (above 8%). We used cluster-robust linear probability modeling with a primary outcome of receiving a prescription for GLP-1RA or SGLT2i, analyzed as a composite endpoint and separately. Our primary predictor was race/ethnicity, with a race-by-calendar-year interaction term. Results: Our sample included 6,607 adults with 27,243 person-years. In 2016, Black adults had an 8.1% lower rate of prescribing than non-Hispanic White patients (p<0.001), with the gap evenly distributed between GLP-1RA and SGLT2i. Hispanic and Asian adults had similar rates to non-Hispanic White patients. Asian patients experienced significantly slower increase in GLP-1RA prescriptions during 2021-2023 (p<0.01). Rates of prescription for Hispanic and Black patients did not change significantly relative to non-Hispanic White patients over time. Conclusion: Black patients had significantly lower prescribing of GLP-1RA or SGLT2i in 2016-2018 and did not experience significant acceleration in prescribing rates in 2019-2023 compared to non-Hispanic White patients. Asian patients had less prescribing of GLP-1RA only in the 2021-2023 period. Utilization of effective new drug classes remains uneven across racial and ethnic groups with type 2 diabetes. Evaluation of interventions to ensure access to GLP-1RA and SGLT2i is needed to promote equitable prescribing and prevent widening disparities in outcomes.
No takes yet. Share an insight, caveat, or question.
TORRES et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: